Bank of Maharashtra raises ₹403cr via QIP

[ad_1]

Read More/Less


Bank of Maharashtra (BoM) has raised ₹403.70 crore via qualified institutions placement (QIP) issue of equity shares.

The public sector bank’s issue committee on Friday approved closure of the QIP issue of equity shares following receipt of application forms for an aggregate of ₹17.03 crore fully paid up equity shares of the bank and funds amounting to ₹403.70 crore in the escrow account from eligible qualified institutional buyers.

Also read: Bank of Maharashtra signs MoU with NABARD

The committee also determined and approved the issue price of ₹23.70 per equity share (including a premium of ₹13.70 per equity share).

The issue price is at a discount of 4.78 per cent (₹1.19 per equity share) to the floor price of ₹24.89 per equity share, BoM said in a regulatory filing. The bank’s QIP issue had opened on July 13.

BoM had allotted 73.60 crore equity shares of ₹10 each to the government of India at an issue price of ₹11.29 per equity share on August 25, 2020, against capital infusion of ₹831 crore. It also raised Tier II capital of ₹505.70 crore in FY21.

[ad_2]

CLICK HERE TO APPLY

To power FY22 advances growth, Bank of Maharashtra eyes ₹2,000 cr fund raise

[ad_1]

Read More/Less


Bank of Maharashtra (BoM) has embarked on an exercise to mop up ₹2,000 crore via qualified institutions placement (QIP) of equity shares in a bid to support its FY22 advances growth target of 16-18 per cent.

The Pune-headquartered public sector bank expects to tap the QIP route, comprising core issue size of ₹1,000 crore and a green shoe option of ₹1,000 crore, by July-end.

AS Rajeev, MD & CEO, observed that the Bank’s target is to increase the advances portfolio to at least ₹1.25 lakh-crore by March-end 2022 against ₹1,07,654-crore as at March-end 2021.

“The envisaged increase in advances of ₹20,000-25,000 crore will absorb around ₹1,500 crore of capital. We will raise another ₹1,000 crore either via Additional Tier-I or Tier-II bonds by March-end 2022,” he said in an interaction with BusinessLine.

The resources raised via QIP and bond routes is expected to take care of the advances growth for the next one to one-and-a-half years. “We posted ₹550 crore net profit in FY21. We are envisaging 25-30 per cent growth in net profit (in FY22). This will also further increase our capital. So, for another two years, we will not require any capital. This is the plan,” Rajeev said.

After the fund raising and plough back of profit, BoM’s capital to risk-weighted assets ratio is likely to go up to 15 per cent by March-end 2022 from 14.49 per cent as at March-end 2021.

Tweaking loan composition

Rajeev underscored that the retail, MSME and agriculture (RAM), and corporate (government guaranteed advances) advances could increase by about ₹15,000 crore and ₹10,000 crore, respectively, so that the retail to wholesale advances ratio in overall portfolio moves to 65:35 as at March-end 2022, against 67:33 as at March-end 2021.

Within emergency healthcare services, BoM’s pharma sector exposure could go up from about 2 per cent of total advances to 4-4.5 per cent. “Funding support is needed by the sector to manufacture Covid-19 related vaccines and medicines,” Rajeev said.

Higher recovery target

BoM is eyeing a higher recovery target of ₹3,000 crore in FY22 against ₹1,644 crore in FY21. “Our target is to bring down Net Non-Performing Assets (NPAs) below 2 per cent by March-end 2022 (from 2.48 per cent as at March-end 2021) and Gross NPAs below 6 per cent (from now 7.23 per cent),” Rajeev added.

[ad_2]

CLICK HERE TO APPLY